These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 22419278)

  • 1. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Moore DH
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD001447. PubMed ID: 22419278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2007 Jan; (1):CD001447. PubMed ID: 17253460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Moore DH
    Cochrane Database Syst Rev; 2001; (4):CD001447. PubMed ID: 11687111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Moore DH
    Cochrane Database Syst Rev; 2000; (2):CD001447. PubMed ID: 10796796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.
    Diana A; Pillai R; Bongioanni P; O'Keeffe AG; Miller RG; Moore DH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006049. PubMed ID: 28067943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
    Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.
    Radunovic A; Annane D; Rafiq MK; Mustfa N
    Cochrane Database Syst Rev; 2013 Mar; (3):CD004427. PubMed ID: 23543531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease.
    Beauverd M; Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2012 Nov; 11():CD002064. PubMed ID: 23152212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole for the treatment of amyotrophic lateral sclerosis.
    Saitoh Y; Takahashi Y
    Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.
    Radunovic A; Annane D; Rafiq MK; Brassington R; Mustfa N
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD004427. PubMed ID: 28982219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
    Pastula DM; Moore DH; Bedlack RS
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD005225. PubMed ID: 23235621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
    Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
    Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
    Pastula DM; Moore DH; Bedlack RS
    Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.
    Ng L; Khan F; Young CA; Galea M
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011776. PubMed ID: 28072907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
    Lacomblez L; Bensimon G; Leigh PN; Guillet P; Meininger V
    Lancet; 1996 May; 347(9013):1425-31. PubMed ID: 8676624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2007 Oct; (4):CD002064. PubMed ID: 17943766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2002; (3):CD002064. PubMed ID: 12137643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.